Vikas Sharma’s Post

🚀 Moderna's innovative portfolio propels it as a top contender against industry giants like Pfizer, Sanofi, AstraZeneca, and GSK. 🌍💉 From their game-changing COVID-19 vaccine to their RSV vaccine approval and promising COVID-19+Flu combo, Moderna is redefining medicine. Their agility and creativity spark curiosity about how they will leverage their competitive edge in vaccines and beyond. To learn more about Moderna’s vaccines portfolio, strategy and upcoming milestones, comment below 👇 for the full copy of this report. #Moderna #Biotechnology #Innovation #Pharmaceuticals #Healthcare #mRNA #GlobalHealth #FutureOfMedicine #Insights #competitiveintelligence #strategy

Sepax three columns were being selected in the new release of USP guideline: 1. SRT SEC-1000 - mRNA Aggregation (PN: 215950-7830) 2. Protemix RP-1000 - mRNA Percent of Fragments (PN: 465950-2110) 3. Zenix SEC-300 - mRNA Aggregation Quantitation (PN: 213300-4615)

🚨 The US Pharmacopeia (USP) has released the 3rd draft version of the guideline "𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚𝐥 𝐏𝐫𝐨𝐜𝐞𝐝𝐮𝐫𝐞𝐬 𝐟𝐨𝐫 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐨𝐟 𝐦𝐑𝐍𝐀 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐚𝐧𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬". This latest update addresses valuable public feedback and includes additional methods to enhance quality assurance for mRNA technologies. As mRNA continues to revolutionize vaccines and therapeutics, these guidelines are key to ensuring consistent quality and safety across the industry. 🧬 💉 Professionals are encouraged to review and provide feedback on the draft by October 31, 2024. Your input can help shape the future of mRNA-based solutions! 📝 #USP #mRNA #Vaccines #Therapeutics #QualityStandards #Biotechnology #HealthcareInnovation #Pharmaceuticals #Regulation

Is faster and more cost-effective mRNA process development and manufacturing part of your 2024 strategy? Europe's mRNA Process Development & Manufacturing Summit returns to Frankfurt this April to help you ensure your drug substance, drug product, and regulatory strategies are better, faster and more scalable in 2024. Download the agenda: https://ter.li/jxbnsz ⚙ Gain clarity on acceptable quality standards and improve comparability changes to accelerate your mRNA therapeutics and vaccines to market with the Medicines and Healthcare products Regulatory Agency and CureVac ⚙ Supercharge your mRNA purity and yield through optimized purification strategies and digital twin modelling approaches, with case studies from AstraZeneca and Sanofi ⚙ Leverage continuous platform manufacturing to achieve accelerated, cost-effective, and consistent high-quality mRNA with insights from The University of Sheffield and King's College London 👀 What's more, save up to €850 on your pass by registering by midnight this Friday, 26th January! Register here to secure your early bird savings: https://ter.li/o7u7en #mRNA #RNA #WorldRNA #ProcessDevelopment #Manufacturing #Vaccine #VaccineDevelopment #TherapeuticDevelopment #InVitroTranscription #Purification #LNP #mRNADevelopment

The #mRNA therapies revolution continues to evolve, offering the potential to accelerate the development of new vaccines and therapeutics. If you’re involved in mRNA product development, expert mRNA characterization and analysis support are essential for navigating the challenges of development and authorization. For nearly three decades, we’ve assisted the world’s most innovative bio/pharmaceutical companies in overcoming challenges related to new product and vaccine development, drug delivery, production, and market release. Explore our specialized expertise in mRNA characterization, GMP analysis, and quality control testing.  Learn more by checking out our mRNA brochure: https://lnkd.in/erry_95M #mRNATherapies #DrugDevelopment #vaccines #Intertek

✨ Stay ahead with the latest trends and insights in the world of pharmaceuticals! Today's Pharma Daily Digest brings you key commercial updates in the industry. 1.      Upstream Bio, a mid-stage respiratory drug developer, and CAMP4 Therapeutics, a Phase 1 regulatory RNA startup, are aiming for IPOs of $182 million and $67 million, respectively 2.      Judo Bio launches with $100M for kidney-targeted siRNA therapies 3. RSV vaccine uptake in the U.S. is off to a slow start this season, with volumes lagging behind 2023. Wall Street analysts monitoring prescriptions report slower-than-anticipated adoption 4.      Biomedical Advanced Research and Development Authority (BARDA) is providing $72 million to Sanofi, GSK, and CSL to strengthen the U.S. supply of bird flu vaccines 5.      Sanofi is selling its rare disease drug, Enjaymo, to Recordati for $825 million upfront. The deal transfers Sanofi’s rare autoimmune medication to the Italian pharmaceutical company 💡 Don't forget to sign up for daily updates within the pharma and biotech industry. #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup

Did you miss the Nanexa team at Capital Markets Day? No problem! You can watch all the presentations – from a deep dive into our PharmaShell ALD platform that formulates drugs as Long Action Injectables, to our ongoing NEX-22 project and collaborations with Novo Nordisk and other Big Pharma, to the global GLP-1 market in diabetes and obesity – here. (Presentations in Swedish, slides in English) https://lnkd.in/d64ue3SG #diabetes #multiplemyeloma #drugformulation #drugdelivery #drugdevelopment #pharmaceuticals #biopharmaceuticals #longactinginjectables #monoclonalantibodies #IR #buinessdevelopment #longactingmonoclonalantibodies #investors

Sanofi Paying Novavax $500 Million Upfront for Its COVID-19 Vaccine Sanofi has announced a deal worth up to $1.4 billion with Novavax for its COVID-19 vaccine, giving the Maryland-based biotech a much-needed boost to its struggling business. The French pharma is dropping $500 million upfront for Novavax’s COVID-19 vaccine, with the goals of co-commercializing its current formulation as well as developing a combination vaccine for COVID and flu. An additional $700 million is up for grabs in milestone payments. Along with another potential $200 million in milestones for additional vaccines made with Novavax’s Matrix adjuvant technology, deal totals $1.4 billion—more than double the biotech’s current market cap of $627 million. Thanks to the infusion of cash, Novavax will be able to lift its prior warning to investors issued in February 2023 expressing doubts over its ability to stay in business, its CEO John Jacobs told CNBC News. https://lnkd.in/ghxGmdnq #aspenalert #biotech #bioprocess

Veeda Group is excited to attend The World Vaccine Congress Europe 2024 to connect with the biopharma industry's foremost experts, pioneers, and key stakeholders. As a leading CRO offering comprehensive end-to-end drug development solutions, we support clients across the US, EU, and Asia-Pacific, with over two decades of expertise.   At the World Vaccine Congress, we are focused on discussing the latest developments in vaccine and biopharmaceutical research ( Biologics, Biosimilar & Therapeutic Proteins). Our participation reflects our commitment to fostering collaborations that drive meaningful progress in the healthcare sector. By engaging with thought leaders and industry experts, we aim to stay informed about the scientific advancements and regulatory trends that shape the future of drug development. Veeda Group is rapidly evolving into an integrated, technology-driven global CRO, positioning ourselves as the go-to partner for contract services. Our data-driven infrastructure reduces study timelines, enabling faster drug launches and supporting the pharmaceutical and biopharmaceutical industries in delivering therapies to those who need them most.   Pre-book a meeting with us to discuss how our cutting-edge solutions can advance your projects and enhance your growth trajectory: https://bit.ly/3UvN7Pl   Sapna Y. R. | Sanjib Banerjee, PhD | Gamlendra (Gamu) Mishra | BIONEEDS INDIA PRIVATE LIMITED | Heads   To know more, write to us at info@veedacr.com or visit www.veedacr.com   Partners in creating a healthier tomorrow.   #VeedaGroup #WorldVaccineCongress #VaccineInnovation #PharmaLeaders #CRO #DrugDevelopment #ClinicalResearch #Biopharma #PharmaIndustry #HealthcareInnovation #Biotechnology #PharmaSolutions #VaccineDevelopment

Webinar on March 22, 2024 @ 3:00 PM IST Registration required: https://lnkd.in/geP4h3p8 Join us for an insightful webinar delving into the intricate world of oligonucleotide therapeutics. Throughout this session, we will examine essential facets of manufacturing, the critical role of USP standards in guaranteeing quality, and optimized workflows designed for thorough quality assessment. From innovative methodologies to scalability considerations, we will explore how adherence to USP standards ensures the integrity of oligonucleotide therapeutics. Additionally, we will reveal strategies for unlocking efficient and comprehensive quality assessment workflows tailored specifically for oligonucleotide therapeutics. Dr. Manoj Metta, Ph.D., EMBA, Marc Lemaitre, Ashish Pargaonkar, Ankush Sharma #USP #agilent #oligonucleotide #pharmaceuticals #biopharmaceuticals #cellandgenetherapy #vaccine